Sign In
Buy INMB
$2.09
+0.180 (+9.42%)
At Close: Aug 07, 2026
Alliance launches with 26 founding companies to develop a national strategy for U.S. biotechnology leadership BOCA RATON, Fla., May 13, 2026 (GLOBE NEWSWIRE) -- INmune Bio, a clinical-stage biotechnol
INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
04:21am, Friday, 08'th May 2026
INmune Bio Inc. (INMB) Q1 2026 Earnings Call Prepared Remarks Transcript
INmune Bio Inc. Announces First Quarter 2026 Results and Provides Business Update
04:00pm, Thursday, 07'th May 2026
BOCA RATON, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient's
LONDON, UK and BOCA RATON, FL, May 05, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (“INmune Bio”), a clinical-stage biotechnology company, and Anthony Nolan, a pioneering UK-based char
INmune Bio Inc. to Report First Quarter 2026 Financial Results and Provide Corporate Update on Thursday, May 7th
08:00am, Thursday, 30'th Apr 2026
Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, April 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage
BOCA RATON, Fla. , April 16, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage biotechnology company focused on developing therapies that harness the patient's
INmune Bio, Inc. (NASDAQ:INMB) Receives Average Rating of “Hold” from Analysts
04:49am, Thursday, 02'nd Apr 2026
Shares of INmune Bio, Inc. (NASDAQ: INMB - Get Free Report) have been assigned a consensus rating of "Hold" from the six brokerages that are covering the firm, MarketBeat.com reports. Two research ana
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
06:52pm, Monday, 30'th Mar 2026
INmune Bio Inc. (INMB) Q4 2025 Earnings Call Transcript
INmune Bio Inc. Announces 2025 Results and Provides Business Update
04:00pm, Monday, 30'th Mar 2026
BOCA RATON, Fla., March 30, 2026 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a late-stage biotechnology company focused on inflammation and immunology, today announces its
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
01:37pm, Friday, 27'th Feb 2026
INmune Bio Inc. (INMB) Discusses XPro1595 Phase II MINDFuL Results and Registrational Strategy in Alzheimer's Disease Transcript
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
12:07am, Friday, 27'th Feb 2026
INmune Bio Inc. (INMB) Discusses MissionEB Phase III Trial and CORDStrom as a Disease-Modifying Therapy for RDEB Transcript
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer's Webinar
09:25am, Monday, 23'rd Feb 2026
Webinar on February 27 at 9:30 AM ET will have key opinion leaders discuss recent and upcoming clinical development of XPro1595 Webinar on February 27 at 9:30 AM ET will have key opinion leaders discu
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
12:15pm, Thursday, 19'th Feb 2026
Clinical investigators from the trial to share real-world experience treating RDEB patients with CORDStrom and present new data from the MissionEB clinical study
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
08:00am, Tuesday, 10'th Feb 2026
Pre-submission package is a process that facilitates early feedback from the United Kingdom (UK) Medicines and Healthcare Products Regulatory Agency (MHRA), designed to streamline the final approval p
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives
09:25am, Tuesday, 27'th Jan 2026
Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO
